

## References

- Albronda T, Gökemeyer JDM and vanHaeften TW (1991):** Transient acute renal failure due to tranexamic acid therapy for diffuse intravascular coagulation. **Neth J Med; 39: 125-127.**
- Allen V, Connell O, C, Liston R and Baskettand T. F. (2003):** Maternal morbidity associated with cesarean delivery without labor compared with spontaneous onset of labor at term. **J Obstet Gynecol; 102: 477-482.**
- Ammar T,Silvay G and Reich DL (1997):** Platelet effects of aprotinin and tranexamic acid. **Br J Anaesth; 78: 32-34.**
- Andersson L, Nilsson IM and Colleen S (1968):** Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. **Br.J Obste Gynaecol;146: 638-642.**
- Anonick PK,Vasudevan J and Gonias SL (1992):** Antifibrinolytic activities of N-acetyl-L-lysine methyl ester, -aminocaproic acid, and tranexamic acid: importance of kringle interactions and active site inhibition.**Acta Obste and Gynecol; 12: 95:100**
- As AK,Hagen P, Webb JB (1996).**Tranexamic acid in the management of postpartum hemorrhage. **Br J Obste Gynaecol;103:1250-1251.**
- Barros FC, Victora CG, Barros AJ, Santos IS, Albernaz E and Matijasevich A (2004):**The challenge of reducing neonatal mortality in middle-income countries.**The Journal of maternal fetal and neonatal meddicin; 365: 847-850.**
- Behague DP, Victora CG. and Barros FC (2002):** Consumer demand for cesarean sections in Brazil: informed decision making, patient

choice, or social inequality? A population based birth cohort study linking ethnographic and epidemiological methods. **BMJ**; **324**: 942-945.

**BekassyZ, and Astedt B (1990).**Treatment with the fibrinolytic inhibitor tranexamic acid-risk for thrombosis? **Acta obstete gynecol scand.**,**69**:353-354

**Benoni G and Fredin H (1996):**Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients. **Br J Bone Joint Surg**; **78**: 430-434.

**Biggs JC, Hugh TB and Dodds AJ (1976):** Tranexamic acid and upper gastrointestinal haemorrhage: a double-blind trial. **South Med**; **17**: 734-738.

**Bolton TJ,Randall K and Yentis SM( 2003) :**effect of the confidential enquiries into maternal deaths on the use of syntocinon at caesarean section in the **UK**.**Anaesthesia** **58**:277-279

**Bonnar J and Sheppard BL (1996):** Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. **BMJ**; **313**: 579-582.

**Boylan J, Klinck J and Sandler A (1996):**Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. **Anaesth**; **85**: 1008-1043.

**Brown RS, Thwaites BK and Mongan PD (1997):**Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: a double-blind, randomized, placebo-controlled trial. **AnesthAnalg**; **85**: 70-75

**CastellinoFJ (1984):**Biochemistry of human plasminogen. **BMJ****10**: 18-23.

**Combs CA, Murphy EL, and Laros RK (1991).** Factors associated with postpartum hemorrhage with vaginal birth. **Obstet Gynecol.77:69-76**

**Cormack F, Chakrabarti RR and Jouhar AJ (1973):** Tranexamic acid in upper gastrointestinal haemorrhage; **Lancet II: 1207-1208.**

**Cox H, Poller L and Thomson J (1969):** Evidence for the release of gastric fibrinolytic activity into peripheral blood.**Br J Obstet Gynecol; 10: 400-404.**

**Davies D and Howell D (1977):** Tranexamic acid and arterial thrombosis. **Lancet1: 41- 49.**

**Declercq E, Barger M, Cabral H, Evans S, Kotelchuck M and Simon C (2007):** Maternal outcomes associated with planned primary cesarean births compared with planned vaginal births. **J ObstetGynecol; 109: 669-677.**

**Declercq E, Sakala C, Corry M and Applebaum S (2006):** Listening to mothers, II: Report of the Second National U.S. Survey of women 's childbearing experiences.**The jornal of maternal-fetal and neonatal Medicine.80:124:130**

**Dildy GA, Paine AR, George NC and Velasco C (2004):** Estimating blood loss. **J Obstet Gynecol; 104: 601-606.**

**Dubber A, McNicolG and Douglas A (1964):**Some properties of the antifibrinolytically active isomer of amino-methyl cyclo-hexane carboxylic acid; **Drugs.80:152:160.**

**Dunn PM , Goa KL (2003):** Tranexamic acid :a review of its use in surgery and other indication. **Drugs;57:1005:10032.**

- **Engqvist A, Broström O and von Feilitzen F (1979):**Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-blind study. **Scand J Gastroenterol; 14: 839-844.**

**Feinmann J(2002):** How to limit cesareans on demand – too NICE to push?  
**Lancet;18: 359:364.**

**Fenton PM (1999):** Blood transfusion for Cesarean section in Malawi. A study of requirements, amount given and effect on mortality.**Anaesth; 54:1055-1058.**

**Fenton P, Whitty C and Reynolds F (2003):** Caesarian section in Malawi: a prospective study of early maternal and perinatal mortality. **BMJ;12: 327-330.**

**FerrerP,Roberts I, Sydenham E(2009).** Anti-fibrinolytic agents in postpartum hemorrhage:a systematic review.**Eur J obste gyncol;9:29-35**

**Fernández L, Liaño F and Navarro J (1995):** Acute renal failure secondary to antifibrinolytic therapy. **Nephron; 69: 478-479.**

**Field CS (1988):** Surgical techniques for cesarean section. **J Obstet GynecolClin North Am; 15:657-672.**

**Fodstad H and Liliequist B (1979):** Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with tranexamic acid;**Acta Obeste Gynecol Scand;69:659-664.**

**Forbes C, Barr R and Reid G (1972):**Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. **BMJ; 2: 311-313.**

**Gai M, Wu L, Su Q and Tatsumoto K (2004):** clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi center, randomized trial. **Eur J Obstet Gynecol Reprod Biol; 112: 145-157.**

**Gamba G, Fornasari PM and Grignani G (1979):** Haemostasis during transvesical prostatic adenomectomy: a controlled trial on the

effect of drugs with antifibrinolytic and thrombin-like activities;  
**Drugs; 39: 89-98.**

**Gohel M, Patel P, Gupta A and Desai P (2007):** Efficacy of tranexamic acid in decreasing blood loss during and after cesarean section: a randomized case controlled prospective study. **J Obstet Gynecol India; 57: 228-235**

**Goldblatt M(1935):** properties of human seminal plasma.**J physiol;84:208-218**

**Gross S,Tilly P,Hentsch D and Vonesch J(2007) :**prostaglandins; **Jornal of expermintal medicine;12:69-77**

**Griffiths A, Watermeyer S, Sidhu K, Amso NN and Nix B (2006):** Female genital tract morbidity and sexual function following vaginal delivery or lower segment cesarean section. **J Obstet Gynaecol; 26:645-649.**

**Guenther CR (1994):** tranexamic acid is better than aprotinin in decreasing bleeding after cardiac surgery. **J Cardio thorac Vasc Anesth; 8: 300-310.**

**GungordukK,Yildirm G, Asicioglu O, GungordukHagen P and Webb JB (1996):**Tranexamic acid in the management of postpartum haemorrhage. **Br J Obstet Gynaecol; 103: 1000-1020.**

**HardyJ and Bélisle S (1997):** Natural and synthetic antifibrinolytics: inert, poisonous or therapeutic agents? **Can J Anaesth; 44: 913-915.**

**HedlundPO (1969):** Antifibrinolytic therapy with Cyklokapron in connection with prostatectomy. **Scand J UrolNephrol; 3: 82-85.**

**HighamJM and Shaw RW (1991):** Risk-benefit assessment of drugs used for the treatment of menstrual disorders. **Drug Saf; 6: 91-96.**

**Hiippala S, Strid L and Wennerstrand M (1997):** Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. **AnesthAnalg; 84: 44-50**

**Hopkins K(2000):** Are Brazilian women really choosing to deliver by cesarean? **Soc Sci Med; 51:725-740.**

**HorrowJ, Van Riper D and Strong M (1995):** The dose-response relationship of tranexamic acid. **Anaesth; 82: 92-97**

**Hoylaerts M, Lijnen H and Collen D (1981):** Studies on the mechanism of the antifibrinolytic action of tranexamic acid. **Biochim Biophys Acta; 673: 75-85.**

**IdoK,Neo M and Asada Y(2000).** Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties. **Arch Orthop Trauma Surg;120:518-520.**

**Kambo I, Bedi N and Dhillon BS (2002):** A critical appraisal of cesarean section rates at teaching hospitals in India. **Int J GyneacolObstet; 79: 151-158.**

**Kang Y(1993):** Clinical use of synthetic antifibrinolytic agents during liver transplantation.South; **Med J; 19: 61-64**

**KasparM, Ramsay MAE and Nguyen A (1997):** Continuous small dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation. **Anesth Analg; 85: 275-281.**

**Katsaros D, Petricevic M and Snow N (1996):**Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients. **Ann ThoracSurg; 61:1123 - 1131.**

**Klenerman L, Mackie I and Chakrabarti R (1977):** Changes in haemostatic system after application of a tourniquet. **Lancet; 1: 962-970.**

**Komoto J, Yamada T, Watanabe K and Takusagawa F (2006):** Crystal structure of prostaglandin F synthase. **Biochemistry; 43: 245-255**

**Kullander S and Nilsson IM (1970):** Human placental transfer of an antifibrinolytic agent (AMCA). *Acta J Obstet Gynecol Scand*; 49: 200-241.

**Landin L and Weiner E (1975):** Late bleeding after conization: the effect of tranexamic acid (Cyklokapron®). **Opusc Med; 20: 274-280.**

**Lavender T, Kingdon C, Hart A, Gyte G, Gabbay M and Neilson J (2005):** Could a randomised trial answer the controversy relating to elective cesarean section? **Lancet, 62: 576-582**

**Liddell H (1993):** Menorrhagia. **N Z Med J; 106: 247-255.**

**Lindoff C, Rybo G and Åstedt B (1993):** Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. **Thromb Haemost; 70: 225-238.**

**Lydon R, Holt V and Martin D (2001):** Delivery method and self-reported postpartum general health status among primiparous women. **Paediatric & Perinatal Epidemiology; 15: 232-240.**

**Mannucci P (1998):** Hemostatic drugs. **N Engl J Med; 339: 237-245.**

**Melander B, Gleniecki G and Granstrand B (1965):** Biochemistry and toxicology of Amikapron®: the antifibrinolytic active isomer of AMCHA. (A comparative study with epsilon-aminocaproic acid). **Acta Pharmacol Toxicol; 22: 332-340.**

**Milsom I, Andersson K and Andersch B (1991):** A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing

intrauterine contraceptive device in the treatment of idiopathic menorrhagia. **Am J ObstetGynecol; 164: 870-879.**

**Morita H, Tachizowa H and Akimoto T (1971):** Evaluation of the safety of tranexamic acid. Teratogenic effects in mice and rats([in Japanese). **Oyo Yakuri; 5:402 -415.**

**Mousa HA and Alfirective Z (2002).**Major potpartum hemorrhage: survey of maternity units in theUnited Kingdom. **Acta Obstet Gynecoscand,81:727-730**

**Movafegh A, Eslamian L, Dorabadi A.(2011):**Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery, **Int J obstetgynecol 95:1-3**

**Munn M, Owen J, Vincent R, Wakefield M, Chestnut D and Hauth J (2001):** Comparison of two oxytocin regiments to prevent uterine atony at cesarean delivery: a randomized controlled trial. **J Obstet Gynaecol; 98: 386-390.**

**Nelson and Randy F. (2005).** An introduction to behavioral endocrinology  
**Drugs;51:70-73**

**Nicolaou, K. and Sorensen .J(1996).** Classics in Total Synthesis.  
**Weinheim, Germany: 115:32-38**

**Novikova n, HofmeyrGJ(2010).**Tranexamic acid for preventing postpartum haemorrhage. **Br J Obstet Gynecol 103:1250-1251**

**Okajima K, Kohno I and Soe G (1994):** Direct evidence for systemic fibrinogenolysis in patients with acquired 2-plasmin inhibitor deficiency. **Am J Hematol; 45: 16-24.**

**PeitsidisP,Kadr AR,(2011):**Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum pharmacother. **Obstet and Gynecol 12(4):503-516**

**Penta de Peppo A, Pierri M and Scafuri A (1995):** Intraoperative



antifibrinolysis and blood-saving techniques in cardiac surgery: prospective trial of three antifibrinolytic drugs. **Tex Heart Inst J; 22:226 -231.**

**Pharmacia and Upjohn (1998):** Cyklokapron. ABPI Compendium of Data Sheets and Summaries of Product characteristics. **Drugs;185:1125-1131**

**Pilbrant A, Schannong M and Vessman J (1981):** Pharmacokinetics and bioavailability of tranexamic acid. **Eur J ClinPharmacol; 20: 65-72**

**PrestonJ, Cameron I and Adams E. (1995):** Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. **Br J ObstetGynaecol; 102: 390-401.**

**Rang H(2007) :** pharmacology: **drugs,538:115-122**

**Reynolds J (1996):** Tranexamic acid, the extra pharmacopoeia. 31st ed. London: **Royal Pharmaceutical Society of Great Britain, 771-772**

**Robblee J(1995):** Graft occlusion following administration of tranexamic acid. *AnesthAnalg.* 80 Suppl SCA; 141.

**Rybo G and Westerberg H (1972):** The effect of tranexamic acid (AMCA) on postoperative bleeding after conization. **Acta J ObstetGynecolScand; 51: 330-347.**

**SakalaC (2006).** Vaginal or cesarean birth? A systematic review to determine what is at stake for mothers and babies. **Br J Obste Gynaecol ;45:235-247.**

**Sekhavat L, Tabatabaai A, Dalili M, Farajkhoda T and Tafti AD (2009):** Efficacy of tranexamic acid in reducing blood loss after cesarean section. **J Matern Fetal Neonatal Med; 22: 72-75.**

**Shimada H, Nagai E and Morita H (1979):**Mutagenicity studies of

tranexamic acid;(in Japanese).**Oyo Yakuri 18: 165-172.**

**Shore L, Reich D and Vela C (1996):** Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery. **Anesth Analg; 83: 18-26.**

**Sheppard BL, Bonnar J (1974).** The ultrastructure of the arterial supply of the human placenta in early and late pregnancy. **J Obstet Gynecol Br common, 81: 497-511.**

**Sindet P (1987):** Distribution of tranexamic acid to plasma and saliva after oral administration and mouth rinsing: a pharmacokinetic study. **J Clin Pharmacol; 27: 1008-1015.**

**Soslau G, Horrow J and Brodsky I (1991):** Effect of tranexamic acid on platelet ADP during extracorporeal circulation. **Am J Hematol; 38: 109-113.**

**Sottrup J, Claeys H and Zajdel M (1978):** The primary structure of human plasminogen: isolation of two lysine-binding fragments and one "mini"-plasminogen (MW, 38,000) by elastase-catalyzed-specific limited proteolysis. **South Med J 3: 191-209.**

**Speekenbrink R, Vonk A and Wildevuur C (1995):** Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. **Ann Thorac Surg; 59: 438-442.**

**Srinil S and Jaisamrarn U (2005):** Treatment of idiopathic menorrhagia with tranexamic acid. **J med Assoc Thai; 88: 145-151.**

**Staël von Holstein C, Eriksson S and Källén R (1987):** Tranexamic acid as an aid to reducing blood transfusion requirements in gastric and duodenal bleeding. **BMJ; 294: 7-10.**

**Stafford I, Gary A, Dildy S, Clark M and Belfort (2008):** Visually estimated and calculated blood loss in vaginal and cesarean delivery. **Am J Obstet. Gynecol; 199: 519-528.**

**Suanberg L, Astedt B. Nilsson IM (1981).** Abruptio placentae treatment

with the fibrinolytic inhibitor tranexamic acid. **Acta Obstet Gynecol Scand**;59:127-130

**Theil P(1981):** Ophthalmological examination of patients in long term treatment with tranexamic acid. **Acta Ophthalmol Copenh**; 59: 237-241.

**Thorsen S (1975):** Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation: influence of aminocarboxylic acids. **Biochim Biophys Acta**; 393: 55-65.

**Tovi D and Thulin C (1972):** The ability of tranexamic acid to cross the blood-brain barrier and its use in patients with ruptured intracranial aneurysms. **Acta Neurol Scand**; 48: 257-265.

**TsementzisS, Honan W and Nightingale S (1990):**Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. **Acta Neurochir**; 103:116-121.

**Van Riper D, Horrow J and Strong M (1993):**Tranexamic acid is hemostatic when administered only during heparinization. **Anesthe**;147: 79:93.

**VerstraeteM (1985):** Clinical application of inhibitors of fibrinolysis. **Drugs**; 29: 236-251.

**Villar J,Valladares E, Wojdyla D, Zavaleta N and Carroli G and Velazco (2005):** Global Survey on Maternal and Perinatal Health Research Group. Cesarean delivery rates and pregnancy outcomes: The 2005 WHO global survey on maternal and perinatal health in Latin America; **Br J Urol**;367: 1819-1829.

**Walzman M and Bonnar J (1982):** Effects of tranexamic acid on the coagulation and fibrinolytic systems in pregnancy complicated by placental bleeding. **Arch Toxicol**; 5: 214-220.

**Wellington K and Wagstaff AJ (2003):**Tranexamic Acid: a review of its

use in the management of menorrhagia. **Drugs; 63: 1417-1425.**

**Ylva V, Karin P and Eva E (2010):** Changed indications for cesarean sections. **Acta J ObstetGynecol; 89: 49-53.**

**Zheng SR, Yang HX and Gupta A(2010).** Clinical study on the efficacy of tranexamic acid in reducing post partum blood loss. **Chin J Obstet Gynecol**

**;36:590-592**